In recent years, the association between the activity of platelets and risk of Alzheimer’s disease (AD) risk has been noticed in numerous studies. However, there in no investigations on the role of specific intracellular pathways to explain this connection. The phosphatidylinositol 3 kinase (PI3K)/AKT pathway is one of the main regulators of cell survival which regulates cellular responses to environmental changes. This pathway also regulates the activity of platelets, and its aberrant activity has been linked to platelet dysfunction in different pathologies. On the other hand, the PI3K/AKT pathway regulates amyloid-β (Aβ) production through regulation of amyloid-β protein precursor (AβPP), BACE-1, ADAMs, and γ-secretase. In addition, alterations in the activity of all of these factors in platelets has been shown in AD-related pathologies. Therefore, this paper aims to introduce the PI3K/AKT pathway as a molecular inducer of platelet dysfunction during aging and AD progression.
BushAI (2003) The metallobiology of Alzheimer’s disease. Trends Neurosci26, 207–214.
2.
HenekaMT, CarsonMJ, El KhouryJ, LandrethGE, BrosseronF, FeinsteinDL, JacobsAH, Wyss-CorayT, VitoricaJ, RansohoffRM (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol14, 388–405.
3.
GowertNS, DonnerL, ChatterjeeM, EiseleYS, TowhidST, MünzerP, WalkerB, OgorekI, BorstO, GrandochM (2014) Blood platelets in the progression of Alzheimer’s disease.. PloS One9, e90523.
4.
KhezriMR, JafariR, YousefiK, ZolbaninNM (2022) The PI3K/AKT signaling pathway in cancer: Molecular mechanisms and possible therapeutic interventions. Exp Mol Pathol127, 104787.
5.
KhezriMR, YousefiK, MahboubiN, HodaeiD, Ghasemnejad-BerenjiM (2022) Metformin in Alzheimer’s disease: An overview of potential mechanisms, preclinical and clinical findings. Biochem Pharmacol197, 114945.
6.
LevengaJ, WongH, MilsteadRA, KellerBN, LaPlanteLE, HoefferCA (2017) AKT isoforms have distinct hippocampal expression and roles in synaptic plasticity. Elife6, e30640.
7.
LongH-Z, ChengY, ZhouZ-W, LuoH-Y, WenD-D, GaoL-C (2021) PI3K/AKT signal pathway: A target of natural products in the prevention and treatment of Alzheimer’s disease and Parkinson’s disease. Front Pharmacol12, 648636.
8.
KhezriMR, YousefiK, EsmaeiliA, Ghasemnejad-BerenjiM (2022) The role of ERK1/2 pathway in the pathophysiology of Alzheimer’s disease: An overviewand update on new developments. Cell Mol Neurobiol, doi: 1 10.1007/s10571-022-01191-x.
9.
ZhangB, WangY, LiH, XiongR, ZhaoZ, ChuX, LiQ, SunS, ChenS (2016) Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer’s disease models. Drug Des Devel Ther10, 1335.
10.
SinghN, BenoitMR, ZhouJ, DasB, Davila-VelderrainJ, KellisM, TsaiL-H, HuX, YanR (2022) BACE-1 inhibition facilitates the transition from homeostatic microglia to DAM-1. Sci Adv8, eabo1286.
11.
YanL, JinY, PanJ, HeX, ZhongS, ZhangR, ChoiL, SuW, ChenJ (2022) 7, 8-dihydroxycoumarin alleviates synaptic loss by activated PI3K-Akt-CREB-BDNF signaling in Alzheimer’s disease model mice. J Agric Food Chem70, 7130–7138.
12.
LiuY, LiuF, Grundke-IqbalI, IqbalK, GongCX (2011) Deficient brain insulin signalling pathway in Alzheimer’s disease and diabetes. J Pathol225, 54–62.
13.
CurtisD, BakayaK, SharmaL, BandyopadhyayS (2020) Weighted burdenanalysis of exome-sequenced late-onset Alzheimer’s cases andcontrols provides further evidence for a rolefor PSEN1 and suggests involvement of the PI3K/Akt/GSK-3βand WNT signalling pathways. Ann Hum Genet84, 291–302.
14.
MountfordJK, PetitjeanC, PutraHWK, McCaffertyJA, SetiabaktiNM, LeeH, TønnesenLL, McFadyenJD, SchoenwaelderSM, EcklyA (2015) The class II PI 3-kinase, PI3KC2α, links platelet internalmembrane structure to shear-dependent adhesive function. NatCommun6, 6535.
15.
HersI (2007) Insulin-like growth factor-1 potentiates platelet activation via the IRS/PI3Kα pathway. Blood110, 4243–4252.
ChenJ, DeS, DamronDS, ChenWS, HayN, ByzovaTV (2004) Impaired platelet responses to thrombin and collagen in AKT-1–deficient mice. Blood104, 1703–1710.
20.
WoulfeD, JiangH, MorgansA, MonksR, BirnbaumM, BrassLF (2004) Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest113, 441–450.
21.
MooreSF, van den BoschMT, HunterRW, SakamotoK, PooleAW, HersI (2013) Dual regulation of glycogen synthase kinase 3 (GSK3) α/β by protein kinase C (PKC) α and Akt promotes thrombin-mediated integrin αIIbβ3 activation and granule secretion in platelets. J Biol Chem288, 3918–3928.
22.
O’BrienKA, Stojanovic-TerpoA, HayN, DuX (2011) An important role for Akt3 in platelet activation and thrombosis. Blood118, 4215–4223.
23.
O’BrienKA, GartnerTK, HayN, DuX (2012) ADP-stimulated activation of Akt during integrin outside-in signaling promotes platelet spreading by inhibiting glycogen synthase kinase-3β
. Arterioscler Thromb Vasc Biol32, 2232–2240.
24.
CarboneMG, PagniG, TagliariniC, ImbimboBP, PomaraN (2021) Can platelet activation result in increased plasma Aβ levels and contribute to the pathogenesis of Alzheimer’s disease?Ageing Res Rev71, 101420.
25.
Ramos-CejudoJ, JohnsonAD, BeiserA, SeshadriS, SalinasJ, BergerJS, FillmoreNR, DoN, ZhengC, KovbasyukZ (2022) Platelet function is associated with dementia risk in the Framingham Heart Study. J Am Heart Assoc11, e023918.
26.
AhnYS, HorstmanLL, JyW, JimenezJJ, BowenB (2002) Vascular dementia in patients with immune thrombocytopenic purpura. Thromb Res107, 337–344.
27.
SchuckF, WolfD, FellgiebelA, EndresK (2016) Increase of α-secretase ADAM10 in platelets along cognitively healthy aging. J Alzheimers Dis50, 817–826.
28.
ColciaghiF, BorroniB, PastorinoL, MarcelloE, ZimmermannM, CattabeniF, PadovaniA, Di LucaM (2002)
α-Secretase ADAM10 as well asαAPPs is reduced in platelets and CSF of Alzheimer diseasepatients. Mol Med8, 67–74.
29.
EvinG, LiQ-X (2012) Platelets and Alzheimer’s disease: Potential of APP as a biomarker. World J Psychiatry2, 102.
30.
VinothkumarG, KrishnakumarS, ShivashekarG, SreedharS, DineshS, SundaramA, BalakrishnanD, VenkataramanP (2018) Therapeutic impact of rHuEPO on abnormal platelet APP, BACE 1, presenilin 1, ADAM 10 and Aβ expressions in chronic kidney disease patients with cognitive dysfunction like Alzheimer’s disease: A pilot study. Biomed Pharmacother104, 211–222.
31.
TangY-D, HasanF, GiordanoFJ, PfauS, RinderHM, KatzSD (2009) Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction: Results of a double-blind, placebo-controlled, randomized trial. Am Heart J158, 941–947.
DonnerL, FeigeT, FreiburgC, ToskaLM, ReichertAS, ChatterjeeM, ElversM (2021) Impact of amyloid-β on Platelet mitochondrial function and platelet–mediated amyloid aggregation in Alzheimer’s disease. Int J Mol Sci22, 9633.
34.
ItoS, KimuraK, HanedaM, IshidaY, SawadaM, IsobeK-i (2007) Induction of matrix metalloproteinases(MMP3, MMP12 and MMP13) expression in the microglia byamyloid-β stimulation via the PI3K/Akt pathway. ExpGerontol42, 532–537.
TogoT, AkiyamaH, KondoH, IkedaK, KatoM, IsekiE, KosakaK (2000) Expression of CD40 in the brain of Alzheimer’s disease and other neurological diseases. Brain Res885, 117–121.
40.
WanP, TanX, XiangY, TongH, YuM (2018) PI3K/AKT and CD40L signaling regulate platelet activation and endothelial cell damage in sepsis. Inflammation41, 1815–1824.
